Simple Summary Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy with a poor prognosis and a dismal survival rate. Oncolytic virus (OV) is an anticancer …
BA Capacio, JSS Narayanan, DA Vicente, Y Liu… - Surgery, 2023 - Elsevier
Background Systemic immunotherapy has had limited clinical benefit in pancreatic ductal adenocarcinoma. This is thought to be due to its desmoplastic immunosuppressive tumor …
JSS Narayanan, T Hayashi, S Erdem… - … for ImmunoTherapy of …, 2023 - ncbi.nlm.nih.gov
Background Pancreatic cancer (PC) has a poor prognosis, and most patients present with either locally advanced or distant metastatic disease. Irreversible electroporation (IRE) is a …
JSS Narayanan, DA Vicente, P Ray, LF Chai, S Erdem… - Surgery, 2020 - Elsevier
Background We describe the use of pancreatic retrograde venous infusion in an orthotopic murine model of pancreatic ductal adenocarcinoma and hypothesize that pancreatic …
Purpose There is a great need to reduce the toxicity of chemotherapy used in the management of pancreatic ductal adenocarcinoma (PDAC). Here we explore if regional …
S Erdem, HJ Lee… - Molecular Cancer …, 2024 - aacrjournals.org
Improvement of outcome in patients with pancreatic ductal adenocarcinoma (PDAC) requires exploration of novel therapeutic targets. Thus far, most studies of PDAC therapies …
Pancreatic cancer is currently the seventh leading cause of cancer death (4.5% of all cancer deaths) while 80%-90% of the patients suffer from unresectable disease at the time of …
In the last two years, the percentage of cases in Peru linked to diarrheal diseases in children has been considerably reduced, demonstrating that even in difficult times health must …